Aadi Bioscience (AADI) – StreetInsider.com Reports
-
Aadi Bioscience (AADI) to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus
-
Aadi Bioscience, Inc. (AADI) Tops Q4 EPS by 5c
-
Aadi Bioscience (AADI) Announces Publication of Long-Term Efficacy and Safety Data Supporting FYARRO
-
Aadi Bioscience (AADI) Files $150M Mixed Shelf
-
Aadi Bioscience Inc (AADI) PT Lowered to $16 at Jefferies
-
Aadi Bioscience Inc (AADI) PT Lowered to $5 at Piper Sandler
-
H.C. Wainwright Downgrades Aadi Bioscience Inc (AADI) to Neutral
-
Aadi Bioscience (AADI) Reports Interim Results from PRECISION1 Trial of nab-Sirolimus
-
Aadi Bioscience Inc (AADI) PT Lowered to $36 at H.C. Wainwright
-
Aadi Bioscience, Inc. (AADI) Tops Q3 EPS by 12c
-
Aadi Bioscience (AADI) Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
-
Aadi Bioscience, Inc. (AADI) Misses Q2 EPS by 5c, revenue in-line
-
Aadi Bioscience (AADI) Reports Q1, Provides Update on PRECISION 1 Tumor Agnostic Trial
-
Aadi Bioscience Inc (AADI) PT Lowered to $37 at Jefferies
-
Aadi Bioscience Inc (AADI) PT Lowered to $45 at H.C. Wainwright
-
Aadi Bioscience, Inc. (AADI) Tops Q4 EPS by 15c
-
Aadi Bioscience (AADI) Appoints Mohammad Hirmand to its Board
-
Aadi Bioscience (AADI) Presents Clinical Data from PRECISION 1 and AMPECT Trials
-
Aadi Bioscience (AADI) Announces Leadership Transition
-
2023 may be the year of the Smid cap in biotech - Piper Sandler
-
Aadi Bioscience, Inc. (AADI) Tops Q3 EPS by 9c
-
Aadi Bioscience (AADI) Announces Management Changes
-
Aadi Bioscience (AADI) Announces 5.8M Share Offering by Selling Stockholders
-
Aadi Bioscience (AADI) Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus
-
Aadi Bioscience (AADI) Announces $72.5 Million Private Placement Equity Financing
-
Aadi Bioscience, Inc. (AADI) Misses Q2 EPS by 12c
-
Aadi Bioscience (AADI) to Join Russell 2000 and Russell 3000 Indexes
-
Aadi Bioscience (AADI) Announces Unique Permanent J-code Issued for FYARRO by Centers for Medicare and Medicaid Services
-
Aadi Bioscience (AADI) Announces US Launch of FYARRO for Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
-
UPDATE: Jefferies Starts Aadi Bioscience Inc (AADI) at Buy
-
Pre-Open Stock Movers 11/23: (AADI) (WDC) (MU) Higher; (BBY) (URBN) (ZM) Lower (more...)
-
Aadi Bioscience (AADI) Granted FDA Approval for FYARRO
-
Aadi Bioscience (AADI) on watch as company's website shows FYARRO is now approved in the U.S.
-
Aadi Bioscience (AADI) Appoints Scott Giacobello as Chief Financial Officer
-
Aadi Bio (AADI) Announces Publication of its Phase 2 Registrational Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology
-
UPDATE: Cowen Starts Aadi Bioscience Inc (AADI) at Outperform
-
Aadi Bioscience (AADI) Files For up to 17.63M Share Secondary Offering
-
Aadi Bioscience (AADI) Appoints Brendan Delaney as Chief Operating Officer
-
UPDATE: Ladenburg Thalmann Starts Aadi Bioscience Inc (AADI) at Buy
-
Piper Sandler Starts Aadi Bioscience (AADI) at Overweight
-
Aadi Bioscience Inc (AADI) PT Raised to $47 at H.C. Wainwright
Back to AADI Stock Lookup